Biophytis (EPA:ALBPS)

BRIEF

published on 10/13/2025 at 07:05, 3 months 17 days ago

Biophytis and Asian Investors to Launch Phase 3 Sarcopenia Trial

Biophytis Phase 3 Trial Sarcopenia BIO101 Asian Investors
REGULATED PRESS RELEASE

published on 10/13/2025 at 07:00, 3 months 17 days ago

BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia
BIOPHYTIS and a Consortium of Investors partner to finance and launch Phase 3 Trial in Sarcopenia, creating a joint venture in Hong Kong with US$20 million investment for clinical operations starting early 2026

Biophytis Joint Venture Phase 3 Trial Sarcopenia Consortium Of Investors
BRIEF

published on 09/30/2025 at 07:05, 4 months ago

Biophytis to Engage in Key Events in Q4 2025

Biophytis Partnerships Longevity Sarcopenia Biotechnology Events
REGULATED PRESS RELEASE

published on 09/30/2025 at 07:00, 4 months ago

Biophytis to Participate in Four Key Events in Q4 2025
Biophytis to participate in four major international events in Q4 2025, showcasing its progress in transformative therapies impacting longevity and seeking new partnerships

Biophytis Partnerships Longevity International Events Transformative Therapies
BRIEF

published on 09/15/2025 at 07:05, 4 months 15 days ago

Biophytis Secures Funding for Obesity Trial in Brazil

Biophytis Brazil Obesity Trial EMBRAPII Clinical Partnerships
REGULATED PRESS RELEASE

published on 09/15/2025 at 07:00, 4 months 15 days ago

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII

Biophytis Public Funding EMBRAPII Obesity Phase 2 Trial Clinical Partners
BRIEF

published on 09/11/2025 at 07:05, 4 months 19 days ago

Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia

Age-related Diseases BIO101 Sarcopenia Clinical Trial Biophytis Strategy Asia And Europe
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 4 months 19 days ago

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
Biophytis announces Phase 3 Sarcopenia Trial Strategy with BIO101 targeting age-related sarcopenia in Europe and Asia, aiming to address a significant unmet medical need and commercial market

Biophytis Clinical Trial Sarcopenia Phase 3 BIO101
BRIEF

published on 09/03/2025 at 07:05, 4 months 27 days ago

Biophytis Advances Obesity Treatment with EMA Approval

Biophytis Obesity Treatment Clinical Trial BIO101 EMA Authorization
REGULATED PRESS RELEASE

published on 09/03/2025 at 07:00, 4 months 27 days ago

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity
Biophytis obtains EMA authorization to launch Phase 2 clinical trial of BIO101 in obesity, marking a significant regulatory milestone in Europe

Biophytis Phase 2 Clinical Trial Obesity EMA Authorization Regulatory Milestone

Published on 01/30/2026 at 14:00, 2 hours 15 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 7 hours 40 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 8 hours 15 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 14 hours ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 16 hours 15 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 16:00, 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dauch Corporation
Published on 01/30/2026 at 15:59, 16 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 01/30/2026 at 15:58, 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Glencore plc
Published on 01/30/2026 at 15:57, 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/30/2026 at 15:56, 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

View all EQS

Published on 01/30/2026 at 08:00, 8 hours 15 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 22 hours 15 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 22 hours 35 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News